Drug-induced hair changes

Key takeaways

• Most drug-related hair loss is diffuse shedding (telogen effluvium) that starts about 2-4 months after a start or dose change and usually recovers after the trigger ends. Chemotherapy is the exception: it causes loss within weeks and sometimes permanent thinning.
• Drugs can also change colour (darker or lighter), texture (curlier, straighter, brittle), lash and brow growth, and cause unwanted hair.
• Many reported links are case reports. For several drugs the "incidence" is a label or safety-database figure with no placebo arm. The table gives the strongest evidence type for each.
• The weight-loss injections give the clearest modern signal: labels report hair loss in about 3-6% on drug versus about 1% on placebo, mostly in women.
• Never stop a prescribed drug because of shedding without the prescriber. Blood thinners, anticonvulsants, thyroid and cancer drugs are examples where stopping can be dangerous.
• Common confounders are the illness itself (thyroid disease, depression, severe illness), weight loss, and low iron or protein.
• A drug started in the same months as a hormonal change (postpartum, menopause, stopping the pill) is easy to blame wrongly.

How drugs change hair

Follicles cycle through growth, regression and rest. Drugs act by killing growing cells (chemotherapy), pushing many follicles into rest early (weight loss, retinoids, anticoagulants and many others), shifting hormone balance (anti-estrogen drugs), immune effects (checkpoint inhibitors), changing pigment-cell signalling (KIT and EGFR inhibitors), or opening channels and receptors that grow hair (minoxidil, prostaglandin analogues). A 2016 review notes that systemic drugs more often cause loss or excess hair than colour change, and that proving causation for colour is difficult. Ricci 2016

Master table

The evidence column refers to the drug-hair link in humans.

Other drugs with strong hair effects are covered elsewhere: finasteride, dutasteride and oral contraceptives.

What the studies show

• A systematic review of 27 studies found many medicines linked to repigmentation of gray hair, mostly in low-quality reports. Yale 2020
• A meta-analysis of 8,052 patients on targeted cancer drugs documented pigment changes of skin and hair. Dai 2017
• A review of hair disorders in cancer patients describes the main patterns: loss, texture change and lash growth. Freites-Martinez 2019
• A review of cosmetic effects of antiseizure drugs covers 127 studies and finds valproate the best documented for hair loss. Asadi-Pooya 2021
• Among 38 Black women, patient accounts of hair after chemotherapy are the main source for texture claims. Wilson 2022
• A 15-patient report suggests scalp cooling may work less well on very thick or coily hair. Dilawari 2021

By hair profile

Pigment effects are most visible in dark hair. Texture effects are mostly known from patient accounts after chemotherapy. Women are over-represented in shedding reports for GLP-1 drugs (about 4-8% vs under 1% in men on the labels).

Myths and facts

• Not all drug shedding is permanent. Most recovers; chemotherapy-persistent loss is the exception.
• The same drug can have opposite effects (imatinib both depigmenting and repigmenting; valproate loss, phenytoin gain).
• Fast weight loss can cause shedding on its own, which is the leading explanation for GLP-1 drug hair loss.

Bottom line

Note when a drug started against when shedding began (2-4 months earlier is typical), and have a clinician check ferritin, thyroid, B12 and vitamin D before blaming the drug. Ask the prescriber about options rather than stopping. Suspected side effects can be reported through national safety systems. Discuss with a doctor.